The components in Hepcvir tablets are involved in inhibiting non structural protein which is essential for viral multiplication. Sofosbuvir is a NS5B inhibitor, Hepcvir is a directly acting anti-hepatitis C viral agent. Sofosbuvir leads to produce pharmacologically active uridine analog triphosphate by intracellular metabolism. Sofosbuvir is inserted into viral HCV DNA by NS5B polymerase and act as a chain terminator.
Brand : Hepcvir
Ingredients : Sofosbuvir
Strength : 400mg
Manufactured : Cipla
Package : 28 Tablets
400mg of Hepcvir The prescribed dose of Hepcvir by blend with different meds; Considerate obtain with genotype I, IV, V or VI ceaseless hepatitis C viral disease: Hepcvir is joined with ribavirin and peg interferon alfa ought to be taken as a once a day. Hepcvir and ribavirin ought to be taken if there should be an occurrence of patients are bothersome to take peg interferon alfa.Patients endured with genotype II ceaseless hepatitis C
Hepcvir ought to be joined with ribavirin as a solitary dose Patients with genotype III hepatitis: Hepcvir joined with ribavirin and peg interferon alfa and it ought to be taken as a solitary dose Generally Hepcvir with ribavirin ought to be taken as single dose In liver transplantation: Hepcvir ought to be simultaneously utilized with ribavirin as a single dose until liver transmission.In pediatric
The usual dose Hepcvir tablet for the children at age 12 or weight of at least 35kg; Without cirrhosis or with child Pugh A or compensated in patients: One tablet of Hepcvir should be combined with weight based ribavirin as a single dose given for 12 weeks. For the patients with decompensated cirrhosis: Combine with ribavirin for 24 weeks the patients should be used One tablet The dosage of ribavirin; Based on body weight of the patients, the dosage of ribavirin should be recommended. < 75kg given 1000mg of ribavirin. At least 75kg given 1200mg of ribavirin. Ribavirin must be administered with food. Dosage adjustment should not be recommended in renal and hepatic impairment patients.
Headache Fatigue Nausea Asthenia Insomnia Anemia HBV reactivation Elevation of lipase & amylase levels Elevation of creatine kinase Cardiac disorder like bradycardia while concomitant with amiodarone Angioedema Skin rashes
Exposure of hepatitis B viral infection occurs in HBV/HCV co infections Serious symptomatic bradycardia while concomitant with amiodarone Risk of depletion of therapeutic effect occurs due to combination of Hepcvir with P-gp inducers or CYP3A4 inducers Fetal adverse occurs while concomitant with ribavirin For all these conditions, withhold or discontinue the therapy with Hepcvir tablets.